Core Insights - Daxor Corporation reported a strong financial performance for 2024, achieving a 116.5% increase in revenue compared to 2023, driven by robust demand for its diagnostic systems [4] - The company is focused on transforming patient care through innovative blood volume analysis systems, with plans to launch a next-generation blood volume analyzer pending FDA approval [2][3] - Daxor's operating division achieved cash-flow break-even in Q1 of 2025, indicating positive operational cash flow [4] Financial Performance - The company reported a NAV of 7.08 in the previous year [1] - Daxor signed 12 new accounts in 2024, contributing to a 60.1% growth in the number of diagnostic kits sold year-over-year [4] - Record-breaking monthly kit revenue was observed in the first two months of 2025, reflecting accelerating adoption of Daxor's products [4] Strategic Developments - Daxor announced the imminent filing for its next-generation blood volume analyzer via the rapid 510(k) approval pathway with the FDA, enhancing clinical workflows in critical care settings [2] - The company secured a 350,000 in NIH and Launch Tennessee grants to support ongoing research and development [4]
Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023